Post-Conference Perspectives: ctDNA for MRD in Lung Cancer

home / news-network / post-conference-perspectives-ctdna-for-mrd-in-lung-cancer

Mark G. Kris, MD, FASCO provides insight on monitoring patients with NSCLC and discusses the developing role of ctDNA.

Current Treatment Options for Patients with NSCLC

EP. 1: Current Treatment Options for Patients with NSCLC

July 7th 2022

Mark G. Kris, MD, FASCO shares an overview of existing treatment options for patients with stage I-III non-small cell lung cancer.

Strategies for Monitoring Patients with NSCLC

EP. 2: Strategies for Monitoring Patients with NSCLC

July 7th 2022

Practical advice on monitoring options for patients with NSCLC treated with definitive radiation therapy or surgery.

Two Key Uses for ctDNA in the Clinical Setting

EP. 3: Two Key Uses for ctDNA in the Clinical Setting

July 7th 2022

Dr. Mark Kris shares insight on ctDNA and its use in detecting MRD in NSCLC.

Review of Recent Data on ctDNA From ASCO 2022

EP. 4: Review of Recent Data on ctDNA From ASCO 2022

July 7th 2022

A comprehensive review of data presented at ASCO 2022 on ctDNA and MRD detection in NSCLC.

Future Implications of ctDNA in the Management of NSCLC

EP. 5: Future Implications of ctDNA in the Management of NSCLC

July 7th 2022

A thoracic oncology expert provides perspective on ctDNA as a tool and its future as part of the NSCLC landscape.